Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions

Author(s):  Svirskis Darren, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei

Issue:  Mar/Apr 2018 - Volume 22, Number 2
View All Articles in Issue

Page(s):  164-171

The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Page 1
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Page 2
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Page 3
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Page 4
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Page 5
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Page 6
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Page 7
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions Page 8

Download in electronic PDF format for $75

Abstract:  Three brands of levothyroxine tablets are currently available in New Zealand (Eltroxin, Mercury Pharma, Synthroid) for extemporaneous compounding into suspensions. This study aims to determine whether tablet brand (i.e., formulation), concentration, storage conditions, as well as pH, impact the stability of compounded levothyroxine suspensions. Using the three available brands of levothyroxine tablets, suspensions were compounded at concentrations of 15 µg/mL and 25 µg/mL and stored at 4°C and 22°C. Samples were withdrawn weekly for 4 weeks, and chemical stability was evaluated using high-performance liquid chromatographic analysis. Physical appearance, ease of resuspension, and pH were also monitored weekly. To evaluate the effect on drug stability, pH modifiers were added to a suspension. As demonstrated by high-performance liquid chromatographic analysis, the suspensions compounded from the Eltroxin and Mercury Pharma tablets were more stable (>90% remaining after 4 weeks) than Synthroid across both storage conditions and concentrations. The drug was more stable at the higher concentration of 25 µg/mL than at 15 µg/mL. Levothyroxine was stable when pH was increased to pH 8 through the addition of sodium citrate; stability was reduced at a lower pH. Storage temperature did not affect the stability of the suspensions during the 4-week study. This is the first study demonstrating the impact of tablet brand, with different excipients, and drug concentrations on stability, and thus the beyond-use date of the compounded levothyroxine liquid formulations. The pH control achieved by sodium citrate, either as an excipient in tablets or an additive during compounding, improved drug stability.

Related Keywords: Darren Svirskis, BPharm, PhD, Shao-Wei Lin, BPharm, Helen Brown, BPharm, Annie Sangaroonthong, BPharm, Daniel Shin, BPharm, Ziqi Wang, BPharm, Hongtao Xu, MSc, PhD, Rebecca Dean, BPharm, Preetika Vareed, BPharm, Maree Jensen, BPharm, Zimei Wu, MSc, PhD, levothyroxine, hypothyroidism, chemical stability, excipients, drug concentration, tablet formulation

Related Categories: EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren
, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
Mar/Apr 2018
Pg. 164-171

Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay
, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
May/Jun 2009
Pg. 250-253

Investigation of Filler Effects on the Compounding of Freeze-dried Orodispersible Tablets Containing Annona muricata Extract
Azman Syahiera Ezzah Noor
, Abd Razak Fashli Syafiq, Kamal Wan Hamirul Bahrin Wan, Zheng Gan Kok, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam, Bin Liew Kai
Nov/Dec 2020
Pg. 509-514

The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja
, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
Mar/Apr 2020
Pg. 140-147

Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Teeranachaideekul Veerawat
, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
Jan/Feb 2021
Pg. 62-72

Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days
Svirskis Darren
, Jaffer Johaina, Agarwal Priyanka, Khan Ayeshah, Kaur Jaskarn, Cheng Alan, Hanning Sara
May/Jun 2020
Pg. 246-251

Setting Up a National System of Compounding Pharmacies: Preventing Error, Assuring Quality, Building Trust
Guedes de Souza Hugo
, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, de Souza Aguiar Simone, do Carmo Garcez Maria
Nov/Dec 2009
Pg. 532-536

Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions
de Oliveira Ferreira Anderson
, Polonini Hudson C, Loures da Silva Sharlene, Cerqueira de Melo Victor Augusto, de Andrade Laura, Fernandes Brandão Marcos Antônio
May/Jun 2017
Pg. 255-263

PostScription: Setting up a National System of Compounding Pharmacies: An Introduction
Guedes de Souza Hugo
, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, de Souza Aguiar Simone, do Carmo Garcez Maria
Sep/Oct 2009
Pg. 447

Comparison of Disintegrant-addition Methods on the Compounding of Orodispersible Tablets
Mahesparan Vishnu A/L
, Bin Abd Razak Fashli Syafiq, Ming Long Chiau, Uddin ABM Helal, Sarker Md Zaidul Islam, Bin Liew Kai
Mar/Apr 2020
Pg. 148-155

Brazilian National System for the Monitoring and Improvement of Compounding Practices: Program Outcomes
Guedes de Souza Hugo
, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, do Carmo Garcez Maria
Mar/Apr 2012
Pg. 98-102

Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4
de Oliveira Ferreira Anderson
, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio
Jul/Aug 2017
Pg. 339-346

Compounded Orodispersible Films with Natural Ingredients for Halitosis: A Clinical Experience
Apolinário Régis De Souza
, Chaves Maria Das Graças Afonso Miranda, Gonçalves Hanny Reis Mockdeci, Martins Isadora Conde Ferreria, De Paula Renée Mazilão, Granato Ana Paula Alves, Polonini Hudson Caetano, Brandão Marcos Antônio Fernandes, Ferreira Anderson De Oliveira, Raposo Nádia Rezende Barbosa
Nov/Dec 2018
Pg. 512-515

Investigation of the Effects of Excipients in the Compounding of Amlodipine Besylate Orally Disintegrating Tablets
Azmi Nurual Hanisah Saiful
, Ming Long Chiau, Uddin A.B.M. Helal, Sarker Zaidul Islam, Bin Liew Kai
Jan/Feb 2022
Pg. 80-87

Application of Co-processed Excipient as a Novel Method to Compound Orally Disintegrating Tablets
Liew Kai Bin
, Hii Shou Hui, Chew Yik Ling, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam
May/Jun 2022
Pg. 255-263

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Orodispersible Films for Compounding Pharmacies
Ferreira Anderson O
, Brandão Marcos Antônio F, Raposo Francisco José, Polonini Hudson C, Raposo Nádia Rezende Barbosa
Nov/Dec 2017
Pg. 454-461

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC
, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2016
Pg. 167-174

Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
May/Jun 2020
Pg. 252-262

Pattern of Extemporaneous Prescriptions and Preparations in a Tertiary Health Institution: A Five-year Assessment
Aghahowa S E
, Egharevba J O, Erhagbe B E, Okoh F
Sep/Oct 2013
Pg. 432-435

Return to Top